Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/jRCT1042250012
jRCT1042250012RecruitingNot Applicable

Feasibility for consensus molecular subtype classification of colorectal cancer using preoperative biopsy tissues; A pilot study

Not provided0 sites8 target enrollmentStarted: June 2, 2025Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Enrollment
8
Primary Endpoint
Percentage of tissue classified as CMS
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Single Arm Study
Intervention Model
Single Assignment
Primary Purpose
Treatment Purpose
Masking
Open(masking Not Used)

Eligibility Criteria

Ages
18age old over to No limit (—)
Sex
All

Inclusion Criteria

  • •(1) Patients 18 years and older with PS (ECOG) of 0 or
  • •(2) Patients with primary colorectal cancer deeper than cT2.

Exclusion Criteria

  • •(1) Patients with a history of chemotherapy or radiotherapy, including treatment for other cancers.
  • •(2) Patients taking antiplatelet or anticoagulant medications.

Outcomes

Primary Outcomes

Percentage of tissue classified as CMS

Percentage of tissue collected using two types of biopsy forceps during preoperative colonoscopy that can be classified as CMS

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Not provided

Similar Trials

Completed
Not Applicable
A studyone
JPRN-UMIN000034518ew drug research center, Inc.200
Not yet recruiting
Not Applicable
Observational prospective cohort study of the niche with a long term follow up.iche Caesarean scar defect.
NL-OMON20181Vu medical center250
Not yet recruiting
Not Applicable
Checklist-based quality improvement program
CTRI/2021/07/034852Tata Memorial Centre
Completed
Not Applicable
An observational study to follow clinical outcomes for the patients participated in the randomized, phase III trial of sequential capecitabine/5FU plus bevacizumab (Cape/5FU-Bmab) to capecitabine/5FU plus oxaliplatin plus bevacizumab (CapeOX/mFOLOFX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancerColorectal Cancer
JPRN-UMIN000036690Department of Clinical Oncology, Kawasaki MEdical School JSWOG311
Recruiting
Not Applicable
Investigation of the Hemodynamic Cardiac Profiler in assessing cardiac indices and clinical performance during exercise and cardiac stressstable ischemic heart disease
NL-OMON23429Hemologic B.V.60